Seminars in arthritis and rheumatism最新文献

{"title":"Clinical prediction models for medication adverse events in patients with rheumatic and musculoskeletal conditions: A systematic literature review","authors":"Christina Diomatari ,&nbsp;Glen P Martin ,&nbsp;David A. Jenkins ,&nbsp;Meghna Jani","doi":"10.1016/j.semarthrit.2025.152728","DOIUrl":"10.1016/j.semarthrit.2025.152728","url":null,"abstract":"<div><h3>Objectives</h3><div>This systematic review aims to identify, summarize, and evaluate the methodological quality of existing clinical prediction models (CPMs) that predict adverse events (AEs) associated with medications prescribed for rheumatic and musculoskeletal diseases (RMDs).</div></div><div><h3>Methods</h3><div>We searched PubMed, Embase, and Medline databases up to March 2024. Studies were included if they developed multivariable CPM predicting AEs in adult patients using RMD medications. Data extraction and quality assessment were conducted using the Critical Appraisal and Data Extraction for Systematic Reviews of Prediction Modelling Studies (CHARMS) and Prediction model Risk Of Bias Assessment Tool (PROBAST) checklists to ensure consistent reporting and assess the risk of bias (ROB).</div></div><div><h3>Results</h3><div>Of 2406 studies identified, 1734 titles/abstracts were screened, and 38 were reviewed in full. Twelve studies reporting 17 CPMs met eligibility criteria. Most CPMs (76.4 %) focused on rheumatoid arthritis and disease modifying anti-rheumatic drugs (DMARDs) such as methotrexate (69.2 %) and biologic drugs (15.3 %). Cox proportional hazards or logistic regression models were commonly used. Twelve models (70.5 %) had high overall ROB due to inappropriate variable selection methods and sample size.</div></div><div><h3>Conclusions</h3><div>This is the first systematic review summarising CPMs for AEs associated with RMD medications. It highlights that existing CPMs are affected by methodological pitfalls, including inappropriate variable selection and lack of clear sample size justification. Future models could consider a broader range of RMDs and medications. Emerging methods such as machine learning with the ability to model complex interactions, and multi-outcome CPMs to predict several AEs to one class of drug may improve predictions.</div></div>","PeriodicalId":21715,"journal":{"name":"Seminars in arthritis and rheumatism","volume":"73 ","pages":"Article 152728"},"PeriodicalIF":4.6,"publicationDate":"2025-04-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143852116","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sleep disorders in rheumatoid arthritis: Incidence, risk factors and association with dementia","authors":"Roslin Jose George ,&nbsp;Rakesh Kumar ,&nbsp;Sara J Achenbach ,&nbsp;Edward Lovering ,&nbsp;Ryan J Lennon ,&nbsp;John M Davis III ,&nbsp;Diego Z. Carvalho ,&nbsp;Cynthia S Crowson ,&nbsp;Elena Myasoedova","doi":"10.1016/j.semarthrit.2025.152722","DOIUrl":"10.1016/j.semarthrit.2025.152722","url":null,"abstract":"<div><h3>Background/Objective</h3><div>We aimed to examine the incidence of sleep disorders (SD) in individuals with rheumatoid arthritis (RA) vs. non-RA comparators, evaluate risk factors for SD, and assess the association between incident SD and dementia in RA.</div></div><div><h3>Methods</h3><div>This retrospective cohort study included residents aged ≥50 years within an 8-county region of Minnesota who first met the 1987 ACR criteria for RA in 1980–2014. Individuals with RA were matched 1:1 with non-RA individuals on age, sex, and calendar year of RA incidence. Data on SD, cardiovascular disease (CVD) risk factors, CVD and other comorbidities were collected from the medical records.</div></div><div><h3>Results</h3><div>Nine hundred thirteen individuals with RA and 913 non-RA comparators were included (mean age: 65 years, 65 % female in both cohorts). During the median follow-up of 10.4 years in RA and 11.0 years in non-RA cohort, SD developed in 234 and 206 individuals, respectively. RA patients experienced an increased risk for any incident SD (HR 1.34; 95 % CI:1.11–1.61) and insomnia (HR 1.34; 95 % CI:1.03–1.73). Obesity, dyslipidemia, presence of CVD, depression, anxiety, and more recent calendar year of RA incidence were associated with increased risk of any SD in RA. There were no significant association between SD overall and by subtype with dementia in RA.</div></div><div><h3>Conclusion</h3><div>Individuals with RA (vs non-RA) experienced a significantly increased risk for any SD, particularly insomnia. CVD and CVD risk factors, as well as depression and anxiety increased the risk for incident SD in RA. There was no significant association between SD and dementia in RA.</div></div>","PeriodicalId":21715,"journal":{"name":"Seminars in arthritis and rheumatism","volume":"73 ","pages":"Article 152722"},"PeriodicalIF":4.6,"publicationDate":"2025-04-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143833799","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Rheumatoid arthritis and the risk of 90-day readmission after hospitalization for heart failure","authors":"Sumanth R. Chandrupatla ,&nbsp;Jasvinder A. Singh","doi":"10.1016/j.semarthrit.2025.152727","DOIUrl":"10.1016/j.semarthrit.2025.152727","url":null,"abstract":"<div><h3>Aims</h3><div>To determine the association of rheumatoid arthritis (RA) diagnosis on the risk of 90-day readmissions and in-hospital mortality during readmission episode within 90 days after index heart failure (HF) hospitalization.</div></div><div><h3>Methods</h3><div>We used the 2016–2019 U.S. Nationwide Readmissions Database (NRD) to examine the association between RA diagnosis and 90-day readmission and in-hospital mortality risk during the 90-day readmission after index HF hospitalization. We performed multivariable-adjusted logistic regression, adjusting for patient demographics, Deyo-Charlson comorbidity index, median household income for patient's ZIP code, primary expected payer, patient state residency status, teaching status of hospital, hospital control, and hospital bed size. We calculated adjusted odds ratios (aOR) and 95 % confidence intervals (95 % CI).</div></div><div><h3>Results</h3><div>Of the 3,718,425 with index HF hospitalizations during 2016–2019, 32.7 % (<em>n</em> = 1,214,185) were readmitted within 90-days of the index heart failure hospitalization. We found that RA diagnosis was significantly associated with both 90-day readmission and in-hospital mortality during readmission within 90 days after index HF hospitalization, with aOR 1.16 (95 % CI, 1.13–1.19), and aOR 1.12 (95 % CI, 1.04–1.20), respectively in multivariable-adjusted analysis. These findings were confirmed in additional sensitivity analysis.</div></div><div><h3>Conclusion</h3><div>We demonstrated a significant association of RA with both 90-day readmission and in-hospital mortality in HF rehospitalizations. Targeted interventions and other treatment options need to be explored to reduce the additional risk of readmission and mortality for patients with RA and HF.</div></div>","PeriodicalId":21715,"journal":{"name":"Seminars in arthritis and rheumatism","volume":"73 ","pages":"Article 152727"},"PeriodicalIF":4.6,"publicationDate":"2025-04-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143864585","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Subclinical coronary artery calcification in systemic sclerosis using high-resolution chest CT: Identification, extent, and disease-specific risk factors","authors":"Esben U. Næser ,&nbsp;Frederik C. Enevoldsen ,&nbsp;Simon Winther ,&nbsp;Morten Bøttcher ,&nbsp;Klaus Søndergaard ,&nbsp;Ellen-Margrethe Hauge","doi":"10.1016/j.semarthrit.2025.152723","DOIUrl":"10.1016/j.semarthrit.2025.152723","url":null,"abstract":"<div><h3>Objectives</h3><div>Early detection of subclinical atherosclerosis is pivotal for preventing symptomatic coronary artery disease. This study aimed to compare the proportion of patients with systemic sclerosis (SSc) having an Agatston coronary artery calcification (CAC) score ≥100 using high-resolution computed tomography (HRCT) chest scans to a background population using cardiac CT scans, and to identify disease-specific risk factors for subclinical CAC in patients with SSc.</div></div><div><h3>Methods</h3><div>Logistic regression models, adjusted for cardiovascular risk factors, evaluated the odds ratio of patients having a CAC score ≥100. CAC scores for the background population were derived from two cardiac CT screening cohorts. CAC scores by HRCT chest scans were calibrated using a conversion factor to adjust for overestimation in comparison to CAC scores obtained from dedicated cardiac CT scans.</div></div><div><h3>Results</h3><div>HRCT chest scans from 394 patients with SSc were evaluated. In total, 116 (29.4 %) had a CAC score of 0, while 162 (41.1 %) had a CAC score ≥100. Disease duration (OR=1.05, 95 % CI 1.01–1.09) and a history of digital ulcers (OR=2.25, 95 % CI 1.31; 3.86) were independently associated with a CAC score ≥100. Compared to the background population, a significantly higher proportion of SSc patients had a CAC score ≥100 (35.0 % vs. 23.2 %, p&lt;0.001).</div></div><div><h3>Conclusion</h3><div>The identification of subclinical atherosclerosis using routine HRCT chest scans in patients with SSc offers the potential to detect individuals at increased risk of developing CAD and guide preventive treatment strategies. Additionally, digital ulcers appear to be a novel risk factor for subclinical CAD in these patients.</div></div>","PeriodicalId":21715,"journal":{"name":"Seminars in arthritis and rheumatism","volume":"73 ","pages":"Article 152723"},"PeriodicalIF":4.6,"publicationDate":"2025-04-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143855789","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Interstitial lung disease in patients with antineutrophil cytoplasmic antibody-associated vasculitis: chest CT patterns and correlation with survival","authors":"Marta Casal Moura ,&nbsp;Yasmeen K. Tandon ,&nbsp;Thomas E. Hartman ,&nbsp;Jay H. Ryu ,&nbsp;Misbah Baqir","doi":"10.1016/j.semarthrit.2025.152726","DOIUrl":"10.1016/j.semarthrit.2025.152726","url":null,"abstract":"<div><h3>Background</h3><div>Interstitial lung disease (ILD) is common in antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV), with usual interstitial pneumonia (UIP) being the most frequent pattern. The impact of different ILD patterns on clinical outcomes remains unclear.</div></div><div><h3>Methods</h3><div>Retrospective cohort study included patients with AAV (MPA and GPA) and ILD confirmed by chest CT scans between 1997 and 2021. ILD patterns were classified according to 2018 Fleischner Society criteria.</div></div><div><h3>Results</h3><div>Of 1862 patients in the Mayo AAV Cohort, 143 (7.7 %) had ILD on chest CT. The median age at the time of ILD diagnosis (occurring before AAV diagnosis in 26.6 %) was 69 years (IQR 61–75); 60 % were male, and 75 % were MPO-positive. On chest CT, “typical UIP” pattern was identified in 44 patients (30.8 %), whereas 13 (9.1 %) manifested “probable UIP” pattern, 37 (25.9 %) “indeterminate for UIP” pattern, and 49 (34.3 %) “non-UIP” pattern. Among MPO-ANCA patients, typical UIP pattern was most common (37.4 %), while non-UIP pattern was most common (58.3 %) among PR3-ANCA patients. Patients with typical UIP pattern, when compared to those with non-UIP pattern, were more commonly male (70.5 %), MPO-ANCA (90.0 %), diagnosed before the onset of AAV (40.9 %), and had reduced diffusion capacity on pulmonary function tests. The presence of typical UIP was related with higher survival at 12 months and 10 years in MPO-ANCA patients when compared to other ILD patterns (IRR 8.201 and IRR 2.179).</div></div><div><h3>Conclusions</h3><div>The typical UIP pattern in AAV-ILD is associated with better survival, particularly in MPO-ANCA patients, suggesting distinct mechanisms for ILD development in MPO vs. PR3-AAV.</div></div>","PeriodicalId":21715,"journal":{"name":"Seminars in arthritis and rheumatism","volume":"73 ","pages":"Article 152726"},"PeriodicalIF":4.6,"publicationDate":"2025-04-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143858804","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Accuracy of the intima-media thickness by ultrasound for the diagnosis of giant cell arteritis: a systematic review","authors":"Camila Pitasi ,&nbsp;Fernando Lamarca ,&nbsp;Veronica Vilela ,&nbsp;Ana Beatriz Vargas-Santos ,&nbsp;Markus Aschwanden ,&nbsp;Stephan Imfeld ,&nbsp;Daniel Staub ,&nbsp;Thomas Daikeler","doi":"10.1016/j.semarthrit.2025.152725","DOIUrl":"10.1016/j.semarthrit.2025.152725","url":null,"abstract":"<div><h3>Objectives</h3><div>To evaluate the performance of quantitative intima-media thickness (IMT) measurement by ultrasound (US) for diagnosing GCA.</div></div><div><h3>Methods</h3><div>A systematic literature review of the following electronic databases was performed: PubMed, Embase, Web of Science, Scopus, Lilacs, and Google Scholar (no date and language restriction, last search June 3, 2024). Studies that tested IMT`s diagnostic accuracy as a primary outcome in GCA suspected patients were included. The quality of the studies was assessed using the QUADAS-2 tool.</div></div><div><h3>Results</h3><div>Among 2786 records screened by title and abstracts, 7 fulfilled the inclusion criteria. The proposed IMT cut-off values for vasculitis in between the studies varied between 0.4 and 0.44, and 0.81 and 1.2 mm for the temporal (TA) and the axillary artery (Axa), respectively. Most cut-off values were post hoc calculated. Diagnostic accuracy vis-à-vis qualitative judgement of the respective segments by US or MRI was high (sensitivities: 76 to 100 %, specificities: 85.7 to 100 %) despite the different cut-offs used. All studies have a high risk of bias in at least two QUADAS-2 domains due to patient selection issues, lack of US blinding, and use of the index test as part of the reference standard.</div></div><div><h3>Conclusion</h3><div>The seven studies had considerable drawbacks due to biases across several domains. This might explain the high reported diagnostic accuracy for defining vasculitis of the TA and Axa segments, despite different cut-off values and reference standards being used in these studies. Reliable IMT cut-off values of the TA and the Axa for diagnosing GCA are not yet available.</div></div>","PeriodicalId":21715,"journal":{"name":"Seminars in arthritis and rheumatism","volume":"73 ","pages":"Article 152725"},"PeriodicalIF":4.6,"publicationDate":"2025-04-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143864529","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Determinants of health-related quality of life in adults living with rheumatoid arthritis: a systematic review","authors":"Nejat Hassen ,&nbsp;Kasra Moolooghy ,&nbsp;Jacek Kopec ,&nbsp;Hui Xie ,&nbsp;Karim M Khan ,&nbsp;Diane Lacaille","doi":"10.1016/j.semarthrit.2025.152717","DOIUrl":"10.1016/j.semarthrit.2025.152717","url":null,"abstract":"<div><h3>Objective</h3><div>To systematically review contemporary studies identifying health-related quality of life (HRQoL) determinants in rheumatoid arthritis (RA) and synthesize the evidence.</div></div><div><h3>Methods</h3><div>Three electronic databases were searched for cross-sectional or prospective cohort studies published 2000 or later that identified HRQoL determinants using multivariable prediction models and evaluated HRQoL using the SF-36/12/8/6D or EQ-5D. Two authors conducted screening, data extraction, and quality assessment. Findings were synthesized using a narrative synthesis approach.</div></div><div><h3>Results</h3><div>Twenty-one studies were included. Seventy determinants were evaluated. Determinants were classified into five domains: (i) sociodemographic, (ii) RA-related, (iii) comorbidities and general health, (iv) health behaviours, and (v) psychosocial. RA-related determinants were the most studied determinants. Forty-four determinants were identified as statistically significant HRQoL determinants. Age and gender were the most evaluated determinants in the sociodemographic domain, but associations between older age and female gender and better HRQoL were inconsistent. Disease duration, disease activity, and physical function were the most evaluated determinants in the RA-related domain. Higher disease activity and worse physical function were associated with lower HRQoL, but association between longer disease duration and HRQoL was inconsistent. All comorbidities identified were associated with lower HRQoL. Exercise and sleep were the only significant determinants in the health behaviours domain and were associated with better HRQoL. Anxiety and depression were the most evaluated psychosocial variables and were associated with lower HRQoL.</div></div><div><h3>Conclusion</h3><div>HRQoL determinants were identified from multiple domains. The existing literature consists mostly of cross-sectional studies. More prospective studies are needed to assess temporal relationship between determinants and HRQoL.</div></div>","PeriodicalId":21715,"journal":{"name":"Seminars in arthritis and rheumatism","volume":"73 ","pages":"Article 152717"},"PeriodicalIF":4.6,"publicationDate":"2025-04-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143837974","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Risk of major adverse cardiovascular events following targeted therapy in patients with rheumatoid arthritis: a real-world analysis stratified by cardiovascular risk","authors":"Seung-Hun You ,&nbsp;Soo-Kyung Cho ,&nbsp;Jeong-Yeon Kim ,&nbsp;Yeo-Jin Song ,&nbsp;Sun-Young Jung ,&nbsp;Yoon-Kyoung Sung","doi":"10.1016/j.semarthrit.2025.152721","DOIUrl":"10.1016/j.semarthrit.2025.152721","url":null,"abstract":"<div><h3>Objective</h3><div>To assess the risk of major adverse cardiovascular events (MACEs) associated with Janus kinase inhibitors (JAKi) compared to tumour necrosis factor inhibitors (TNFi) in rheumatoid arthritis (RA).</div></div><div><h3>Methods</h3><div>Using the Korean nationwide claims database, we identified patients with RA prescribed JAKi or TNFi between 2015 and 2019. Patients were stratified into two groups based on cardiovascular (CV) risk and matched within each group using propensity score matching at a ratio of up to 1:4. Follow-up continued until MACE, death, or treatment discontinuation. Hazard ratios with 95 % confidence intervals were calculated using the Cox proportional hazards model. Additionally, MACE risk was analyzed separately in patients with and without a history of cardiovascular disease (Hx.CVD).</div></div><div><h3>Results</h3><div>A total of 7575 patients prescribed either JAKi or TNFi were included. After propensity score matching, the hazard ratio for MACEs comparing JAKi to TNFi was 0.77 (95 % confidence interval 0.45–1.34) in the high CV risk group. No significant differences in MACEs were observed between JAKi and TNFi users across the low CV risk group, as well as Hx.CVD and non-Hx.CVD groups. Subgroup and sensitivity analyses showed no statistically significant differences in the risk of individual MACE components, such as myocardial infarction, stroke, or heart failure.</div></div><div><h3>Conclusion</h3><div>No significant differences in the risk of MACEs were observed between JAKi and TNFi users across various CV risk groups and in those with or without Hx.CVD. Subgroup and sensitivity analyses supported these findings, showing no elevated risks for individual MACE components.</div></div>","PeriodicalId":21715,"journal":{"name":"Seminars in arthritis and rheumatism","volume":"73 ","pages":"Article 152721"},"PeriodicalIF":4.6,"publicationDate":"2025-04-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143858803","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Predicting anxiety and depression in systemic lupus erythematosus: the role of inflammation, sociodemographic variables and clinical factors","authors":"Margot Sigel ,&nbsp;Carolina Muñoz-Grajales ,&nbsp;Michelle L. Barraclough ,&nbsp;Juan P Diaz-Martinez ,&nbsp;Mahta Kakvan ,&nbsp;Roberta Pozzi Kretzmann ,&nbsp;M Carmela Tartaglia ,&nbsp;Lesley Ruttan ,&nbsp;May Y Choi ,&nbsp;Simone Appenzeller ,&nbsp;Dennisse Bonilla ,&nbsp;Patricia Katz ,&nbsp;Dorcas E. Beaton ,&nbsp;Robin Green ,&nbsp;Dafna D. Gladman ,&nbsp;Joan E. Wither ,&nbsp;Alastair J. Flint ,&nbsp;Zahi Touma ,&nbsp;Kathleen S. Bingham","doi":"10.1016/j.semarthrit.2025.152718","DOIUrl":"10.1016/j.semarthrit.2025.152718","url":null,"abstract":"<div><h3>Objectives</h3><div>Characterizing the contribution of specific pro-inflammatory mediators (analytes) to depression and anxiety in systemic lupus erythematosus (SLE) is a crucial step in illuminating the mechanisms of these disabling symptoms. The aims of this study were to investigate i) the relationship between depression and anxiety symptoms with relevant clinical and sociodemographic variables and neuroinflammation-associated analytes in a cohort of SLE patients, and ii) the ability of models including these sociodemographic, clinical and biological variables to discriminate between SLE patients with and without clinically significant depression or anxiety.</div></div><div><h3>Methods</h3><div>This is a cross-sectional study of baseline data from participants enrolled in a longitudinal study of cognition in SLE (<em>N</em> = 238). We examined the relationship between serum concentrations of a group of analytes associated with neuroinflammation, relevant sociodemographic and clinical variables and i) depression (measured with the Beck Depression Inventory-II) and anxiety (measured with the Beck Anxiety Inventory) scores, as well as between clinically significant depression and anxiety symptoms (defined using cut-off scores validated in SLE) via random forests. We generated model performance statistics from these models using confusion matrices.</div></div><div><h3>Results</h3><div>Depression is most influenced by duration of SLE and, to a lesser extent, concentrations of the analytes MMP-9. Anxiety is most influenced by the analytes NGAL and IFN- Ɣ, with other variables being less influential. The multivariate models exhibited AUCs of 0.85 (depression), 0.77 (anxiety) and 0.82 (both depression and anxiety).</div></div><div><h3>Conclusions</h3><div>The findings of this exploratory study provide potential models predicting depression and anxiety symptoms in SLE. This produces a basis for further research building a conceptual model explaining the mechanisms of these important patient-centered outcomes in SLE.</div></div>","PeriodicalId":21715,"journal":{"name":"Seminars in arthritis and rheumatism","volume":"73 ","pages":"Article 152718"},"PeriodicalIF":4.6,"publicationDate":"2025-04-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143874147","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"New anti-TNF biologics in RA: What is new and what is old?","authors":"Tsutomu Takeuchi","doi":"10.1016/j.semarthrit.2025.152693","DOIUrl":"10.1016/j.semarthrit.2025.152693","url":null,"abstract":"<div><div>This review summarizes the recent advancement of fragmented immunoglobulin molecules targeting on Tumot Necrosis Factor (TNF) alpha and highlighted the nanobody, which is the first approved product for the patients with rheumatoid arthritis (RA), ozoralizumab (OZR). Background for the clinical development, pharmakokinetics, and clinical trial data for OZR were shown. It has been approved in Japan in 2022 and marked as the fixth products of TNF inhibitors for RA in Japan. The similarities and differences among these products are discussed in this review.</div></div>","PeriodicalId":21715,"journal":{"name":"Seminars in arthritis and rheumatism","volume":"72 ","pages":"Article 152693"},"PeriodicalIF":4.6,"publicationDate":"2025-04-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143781121","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}